نتائج البحث

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

• Authors : Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra

Subjects: renal cell carcinoma; metastatic; immune checkpoint inhibitors

• Source: Acta Oncologica. 64:1355-1364

تفاصيل العنوان

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

• Authors : Regeneron Pharmaceuticals; Vanderbilt-Ingram Cancer Center; Brian Rini, Sponsor-investigator

• Source: A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell

تفاصيل العنوان

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

• Source: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialAtkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M,

تفاصيل العنوان

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

• Source: Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab

تفاصيل العنوان

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

• Source: A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors

تفاصيل العنوان

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

• Source: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With

تفاصيل العنوان

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

• Source: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsChae YK, Othus M, Patel SP, Backes FJ, O'Malley DM, Cristea M, Naing A, Kurnit K, Eskander RN, T Goodrich S, Robinson WR, Scalici J,

تفاصيل العنوان

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

• Source: A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced

تفاصيل العنوان

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

• Source: A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)Girardi DM, Niglio SA, Mortazavi A, Nadal R, Lara P, Pal SK,

تفاصيل العنوان

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

• Source: Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid

تفاصيل العنوان